Form 4: Arcutis Biotherapeutics CFO David Topper Reports Stock Transactions Following PSU Vesting
SEC Form 4 Filing
Arcutis Biotherapeutics' CFO, David Topper, reports acquisition and disposal of common stock related to performance stock units (PSUs) vesting and subsequent sell-to-cover transactions.
Summary
- On September 21, 2024, David Topper, CFO of Arcutis Biotherapeutics, acquired 60,000 shares of common stock due to the vesting of Performance Stock Units (PSUs).
- 50% of these shares vested on September 21, 2024, and the remaining 50% will vest on September 21, 2025, contingent upon continued service.
- On September 24, 2024, Topper disposed of 11,626 shares at a weighted average price of $9.4843 per share to cover tax withholding requirements related to the PSU vesting.
- The shares were sold in multiple transactions at prices ranging from $9.40 to $9.61.
- Following these transactions, Topper beneficially owns 158,374 shares of Arcutis Biotherapeutics common stock.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock transactions and doesn't inherently indicate positive or negative sentiment. It's a neutral event.
Future Outlook
The remaining 50% of the Performance Stock Units are scheduled to vest on September 21, 2025, contingent upon the Reporting Person's continued service with the Company.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- Shareholders are informed about the CFO's stock transactions, providing transparency.
- The transactions have a minor impact on the overall share float.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Initial grant date of Performance Stock Units (PSUs) |
| 09/21/2024 | Vesting Commencement Date: 50% of PSUs vest |
| 09/24/2024 | Sale of 11,626 shares to cover tax withholding |
| 09/21/2025 | Remaining 50% of PSUs vest, subject to continued service |
| 09/25/2024 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.